Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review

被引：15

作者：

Pareek, Vipul ^{[1
]}

Welch, Mary ^{[1
]}

Ravera, Elizabeth ^{[1
]}

Zampolin, Richard L. ^{[2
]}

Sequist, Lecia V. ^{[3
,4
]}

Halmos, Balazs ^{[1
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10467 USA

[2] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Radiol, Bronx, NY 10467 USA

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Harvard Med Sch, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期

关键词：

D O I：

10.1016/j.jtho.2016.07.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E135 / E139

页数：9

共 26 条

[1] AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies [J].

Ahn, M. J. ;

Tsai, C. M. ;

Yang, J. C. H. ;

Shepherd, F. A. ;

Satouchi, M. ;

Kim, D. W. ;

Bazhenova, L. ;

Hirashima, T. ;

Rukazenkov, Y. ;

Cantarini, M. ;

Mann, H. ;

Ramalingam, S. S. ;

Mitsudomi, T. ;

Jaenne, P. A. ;

Goss, G. D. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S625-S626

[2]

[Anonymous], MOL CANC THER

[3]

Ballard P, 2015, J THORAC ONCOL, V10, pS300

[4] Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].

Chaft, Jamie E. ;

Oxnard, Geoffrey R. ;

Sima, Camelia S. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303

[5] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[6] Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation [J].

Elmeliegy, Mohamed A. ;

Carcaboso, Angel M. ;

Tagen, Michael ;

Bai, Feng ;

Stewart, Clinton F. .

CLINICAL CANCER RESEARCH, 2011, 17 (01) :89-99

[7]

Goldman JW, 2016, ASCO M, V34, P9045

[8] "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer [J].

Grommes, Christian ;

Oxnard, Geoffrey R. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Pao, William ;

Holodny, Andrei I. ;

Clarke, Jennifer L. ;

Lassman, Andrew B. .

NEURO-ONCOLOGY, 2011, 13 (12) :1364-1369

[9]

He Y, 2015, NEW ENGL J MED, V373, P578, DOI 10.1056/NEJMc1506831

[10] In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer [J].

Hirano, Toshiyuki ;

Yasuda, Hiroyuki ;

Tani, Tetsuo ;

Hamamoto, Junko ;

Oashi, Ayano ;

Ishioka, Kota ;

Arai, Daisuke ;

Nukaga, Shigenari ;

Miyawaki, Masayoshi ;

Kawada, Ichiro ;

Naoki, Katsuhiko ;

Costa, Daniel B. ;

Kobayashi, Susumu S. ;

Betsuyaku, Tomoko ;

Soejima, Kenzo .

ONCOTARGET, 2015, 6 (36) :38789-38803

← 1 2 3 →